The effect of clinical pharmacist-led services with one-year follow-up in patients with type 2 diabetes mellitus: a randomized controlled trial

Sumeyra Lubeyne Soylemez; Akın Dayan; Refik Demirtunç; Mesut Sancar

doi:10.12991/jrespharm.1720077

The effect of clinical pharmacist-led services with one-year follow-up in patients with type 2 diabetes mellitus: a randomized controlled trial

Abstract

Backgrounds: This prospective randomized controlled study aims to assess medication adherence, diabetes knowledge, related treatment outcomes, and quality of life of patients with type 2 diabetes mellitus (T2DM). Methods: The study was conducted in a training and research hospital in Istanbul within one-year follow-up. Medication adherence, disease knowledge levels and quality of life were measured using the Morisky–Green–Levine (MGL) scale, a 18-item self-structured scale and the WHOQOL-BREF questionnaire, respectively. Primary endpoints of the study were HbA1c level, quality of life, knowledge level, and medication adherence. Results: The study included 114 patients. Of them, 57 patients were in the intervention group (IG) and received pharmaceutical care services. The mean diabetes age among the patients was 14.6±7.3 years. Of them, 89.4% had low levels of education. Half of the participants were female. Adherence and knowledge levels improved significantly at the end of the study (p=0.021 and p=0.047, respectively) in IG. A statistically significant difference was observed only in the physical dimension of the WHOQOL-BREF questionnaire (p=0.004) in IG. HbA1c levels of the patients decreased by 1.36% and the decrease in fasting blood glucose levels was also statistically significant (p<0.001) in IG. In addition, 86 drug-related problems were suggested to the specialist, and 81.39% of them were accepted. At the end of the study, 31.81% of patients in the IG reached the treatment goal. Conclusions: The clinical pharmacist intervention decreased HbA1c levels and helped to improve glycemic control by increasing the patients' knowledge levels and medication adherence within a one-year follow-up.

Keywords

References

1. Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2023;402(10397):203-34. http://dx.doi.org/10.1016/S0140-6736(23)01301-6
2. 2025. In: IDF Diabetes Atlas [Internet]. International Diabetes Federation, 2025. 11. [6].
3. 2025. In: IDF Diabetes Atlas [Internet]. International Diabetes Federation. 11. [41].
4. 2025. In: IDF Diabetes Atlas [Internet]. International Diabetes Federation. 11. [106].
5. Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. Journal of Managed Care Pharmacy. 2012;18(7):516-26. http://dx.doi.org/10.18553/jmcp.2012.18.7.516
6. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405-12. http://dx.doi.org/10.1136/bmj.321.7258.405
7. Grant R, Adams AS, Trinacty CM, Zhang F, Kleinman K, Soumerai SB, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes care. 2007;30(4):807-12. http://dx.doi.org/10.2337/dc06-2170
8. Sisson E, Kuhn C. Pharmacist roles in the management of patients with type 2 diabetes. Journal of the American Pharmacists Association. 2009;49(5):S41-S5. http://dx.doi.org/10.1331/JAPhA.2009.09075

9. Schapansky LM, Johnson JA. Pharmacists’ attitudes toward diabetes. Journal of the American Pharmaceutical Association (1996). 2000;40(3):371-7. http://dx.doi.org/10.1016/s1086-5802(16)31085-3
10. Lee M. Automation and the future practice of pharmacy--changing the focus of pharmacy. Pharmacy practice management quarterly. 1995;15(3):23-35. http://dx.doi.org/10.1177/1715163518793844a
11. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. American journal of hospital pharmacy. 1990;47(3):533-43. http://dx.doi.org/10.1093/ajhp/47.3.533
12. Shao H, Chen G, Zhu C, Chen Y, Liu Y, He Y, et al. Effect of pharmaceutical care on clinical outcomes of outpatients with type 2 diabetes mellitus. Patient preference and adherence. 2017;11:897. http://dx.doi.org/10.2147/PPA.S92533
13. Plumridge RJ, Wojnar-Horton RE. A review of the pharmacoeconomics of pharmaceutical care. Pharmacoeconomics. 1998;14(2):175-89. http://dx.doi.org/10.2165/00019053-199814020-00006
14. Chung WW, Chua SS, Lai PSM, Chan SP. Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. Patient preference and adherence. 2014;8:1185. http://dx.doi.org/10.2147/PPA.S66619
15. Hening WN, Sartika RAD, Sauriasari R. Effect of hospital pharmacist counseling on clinical outcomes of type 2 diabetes mellitus outpatients. Journal of research in pharmacy practice. 2019;8(3):155. http://dx.doi.org/10.4103/jrpp.JRPP_19_67
16. Erku DA, Ayele AA, Mekuria AB, Belachew SA, Hailemeskel B, Tegegn HG. The impact of pharmacist-led medication therapy management on medication adherence in patients with type 2 diabetes mellitus: a randomized controlled study. Pharmacy Practice (Granada). 2017;15(3). http://dx.doi.org/10.18549/PharmPract.2017.03.1026
17. Sabaté E, Organization WH. Adherence to long-term therapies: policy for action: meeting report, 4-5 June 2001. World Health Organization; 2001.
18. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care. 1986:67-74. http://dx.doi.org/10.1097/00005650-198601000-00007
19. Ting CY, Adruce SAZ, Lim CJ, Abd Jabar AHA, Ting RS-K, Ting H, et al. Effectiveness of a pharmacist-led structured group-based intervention in improving medication adherence and glycaemic control among type 2 diabetes mellitus patients: A randomized controlled trial. Research in Social and Administrative Pharmacy. 2021;17(2):344-55. http://dx.doi.org/10.1016/j.sapharm.2020.03.026
20. Syarifuddin S, Nasution A, Aminah Dalimunthe K. Impact of pharmacist intervention on improving the quality of life of patients with type 2 diabetes mellitus. Open access Macedonian journal of medical sciences. 2019;7(8):1401. http://dx.doi.org/10.3889/oamjms.2019.140
21. Lim PC, Lim K, Embee ZC, Hassali MA, Thiagarajan A, Khan TM. Study investigating the impact of pharmacist involvement on the outcomes of diabetes medication therapy adherence program Malaysia. Pakistan journal of pharmaceutical sciences. 2016;29(2).
22. Shareef J, Fernandes J, Samaga L. Assessment of clinical pharmacist interventions in drug therapy in patients with diabetes mellitus in a tertiary care teaching hospital. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2016;10(2):82-7. http://dx.doi.org/10.1016/j.dsx.2015.09.017
23. Marathe PH, Gao HX, Close KL. American D iabetes A ssociation S tandards of M edical C are in D iabetes 2017. Wiley Online Library; 2017. http://dx.doi.org/10.1111/1753-0407.12524
24. Federation D. Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. 2012. 2014. http://dx.doi.org/10.1016/j.diabres.2012.10.001
25. Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes/metabolism research and reviews. 2019;35(6):e3158. http://dx.doi.org/10.1002/dmrr.3158
26. Porselvi A. A Review on the Need of Advanced Clinical Pharmacy Education Services for Diabetes Prevention and Management in India in comparison with International Standards. Research Journal of Pharmacy and Technology. 2021;14(1):493-500. http://dx.doi.org/10.5958/0974-360X.2021.00090.1
27. Nascimentoa T, Braz N, Gomes E, Fernandez-Arche A, De La Puerta R. Self-care improvement after a pharmaceutical intervention in elderly type 2 diabetic patients. Current diabetes reviews. 2016;12(2):120-8. http://dx.doi.org/10.2174/1573399811666150722130232
28. 6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes—2024. Diabetes care. 2024;47(Supplement_1):S111-S25. http://dx.doi.org/10.2337/dc24-S006
29. Palaian S, Acharya LD, Rao PGM, Shankar PR, Nair NM, Nair NP. Knowledge, attitude, and practice outcomes: evaluating the impact of counseling in hospitalized diabetic patients in India. P AND T. 2006;31(7):383.
30. Cani CG, Lopes LdSG, Queiroz M, Nery M. Improvement in medication adherence and self-management of diabetes with a clinical pharmacy program: a randomized controlled trial in patients with type 2 diabetes undergoing insulin therapy at a teaching hospital. Clinics. 2015;70(2):102-6. http://dx.doi.org/10.6061/clinics/2015(02)06
31. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. British journal of clinical pharmacology. 2009;67(5):547-57. http://dx.doi.org/10.1111/j.1365-2125.2009.03391.x
32. Korcegez EI, Sancar M, Demirkan K. Effect of a pharmacist-led program on improving outcomes in patients with type 2 diabetes mellitus from Northern Cyprus: a randomized controlled trial. Journal of managed care & specialty pharmacy. 2017;23(5):573-82. http://dx.doi.org/10.18553/jmcp.2017.23.5.573
33. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta-analysis in diabetes management. Annals of pharmacotherapy. 2007;41(10):1569-82. http://dx.doi.org/10.1345/aph.1K151
34. Hayward RA, Krein SL, Vijan S. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005;11:253.
35. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2008;28(4):421-36. http://dx.doi.org/10.1592/phco.28.4.421
36. Krass I, Armour C, Mitchell B, Brillant M, Dienaar R, Hughes J, et al. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. Diabetic Medicine. 2007;24(6):677-83. http://dx.doi.org/10.1111/j.1464-5491.2007.02143.x
37. Machado M, Bajcar J, Guzzo GC, Einarson TR. Hypertenion: Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Annals of Pharmacotherapy. 2007;41(11):1770-81. http://dx.doi.org/10.1345/aph.1K311
38. Johnson CL, Nicholas A, Divine H, Perrier DG, Blumenschein K, Steinke DT. Outcomes from DiabetesCARE: a pharmacist-provided diabetes management service. Journal of the American Pharmacists Association. 2008;48(6):722-30. http://dx.doi.org/10.1331/JAPhA.2008.07133
39. Nola KM, Gourley DR, Portner TS, Gourley GK, Solomon DK, Elam M, et al. Clinical and humanistic outcomes of a lipid management program in the community pharmacy setting. Journal of the American Pharmaceutical Association (1996). 2000;40(2):166-73. http://dx.doi.org/10.1016/s1086-5802(16)31060-9
40. Siaw M, Ko Y, Malone D, Tsou K, Lew YJ, Foo D, et al. Impact of pharmacist‐involved collaborative care on the clinical, humanistic and cost outcomes of high‐risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. Journal of clinical pharmacy and therapeutics. 2017;42(4):475-82. http://dx.doi.org/10.1111/jcpt.12536
41. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Annals of Pharmacotherapy. 1996;30(3):238-43. http://dx.doi.org/10.1177/106002809603000305
42. Ahmad AD, Elnour AA, Yousif MA, Farah FH, Akasha HA, Abasaeed A, et al. Pharmacist’s interventions to improve clinical outcomes in patients with type 2 diabetes mellitus: Nyala City, South Darfur State, Sudan. International Journal of Diabetes in Developing Countries. 2015;35(4):578-87. http://dx.doi.org/10.1007/s13410-015-0349-5
43. Bahar G, SAVAŞ HA, Ünal A, SAVAŞ E, Kaya H, Bahar A. Morisky Tedavi Uyum Ölçeğinin iki uçlu duygudurum bozukluğu için geçerlilik ve güvenilirlik çalışması. Anatolian Journal of Psychiatry/Anadolu Psikiyatri Dergisi. 2014;15(2). http://dx.doi.org/10.5455/apd.39827
44. Eser E, Fidaner H, Fidaner C, Eser SY, Elbi H, Göker E. WHOQOL-100 ve WHOQOL-BREF'in psikometrik özellikleri. Psikiyatri Psikoloji Psikofarmakoloji (3P) Dergisi. 1999;7(Suppl 2):23-40.
45. İDİZ C, ÇELİK S, BAĞDEMİR E, DİŞSİZ M, SATMAN İ. Turkish Adaptation of Michigan Diabetes Research and Training Center's Revised Diabetes Knowledge Test and Determination of Factors Affecting the Knowledge Level of Diabetic Individuals. Turkish Journal of Endocrinology & Metabolism. 2020;24(1). http://dx.doi.org/10.25179/tjem.2019-71974 46. Quandt SA, Ip EH, Kirk JK, Saldana S, Chen S-H, Nguyen H, et al. Assessment of a short diabetes knowledge instrument for older and minority adults. The Diabetes Educator. 2014;40(1):68-76. http://dx.doi.org/10.1177/0145721713508824

Details

Primary Language

English

Subjects

Clinical Pharmacy and Pharmacy Practice

Journal Section

Research Article

Authors

Sumeyra Lubeyne Soylemez ^*
Türkiye

Akın Dayan
0000-0002-5839-9689
Türkiye

Refik Demirtunç
Türkiye

Mesut Sancar
0000-0002-7445-3235
Türkiye

Publication Date

March 15, 2026

Submission Date

June 15, 2025

Acceptance Date

July 28, 2025

Published in Issue

Year 2026 Volume: 30 Number: 2

DOI

https://doi.org/10.12991/jrespharm.1720077

IZ

https://izlik.org/JA84ME29NW

Cite

RIS / Bibtex

APA

Soylemez, S. L., Dayan, A., Demirtunç, R., & Sancar, M. (2026). The effect of clinical pharmacist-led services with one-year follow-up in patients with type 2 diabetes mellitus: a randomized controlled trial. Journal of Research in Pharmacy, 30(2), 730-742. https://doi.org/10.12991/jrespharm.1720077

AMA

1.Soylemez SL, Dayan A, Demirtunç R, Sancar M. The effect of clinical pharmacist-led services with one-year follow-up in patients with type 2 diabetes mellitus: a randomized controlled trial. J. Res. Pharm. 2026;30(2):730-742. doi:10.12991/jrespharm.1720077

Chicago

Soylemez, Sumeyra Lubeyne, Akın Dayan, Refik Demirtunç, and Mesut Sancar. 2026. “The Effect of Clinical Pharmacist-Led Services With One-Year Follow-up in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial”. Journal of Research in Pharmacy 30 (2): 730-42. https://doi.org/10.12991/jrespharm.1720077.

EndNote

Soylemez SL, Dayan A, Demirtunç R, Sancar M (March 1, 2026) The effect of clinical pharmacist-led services with one-year follow-up in patients with type 2 diabetes mellitus: a randomized controlled trial. Journal of Research in Pharmacy 30 2 730–742.

IEEE

[1]S. L. Soylemez, A. Dayan, R. Demirtunç, and M. Sancar, “The effect of clinical pharmacist-led services with one-year follow-up in patients with type 2 diabetes mellitus: a randomized controlled trial”, J. Res. Pharm., vol. 30, no. 2, pp. 730–742, Mar. 2026, doi: 10.12991/jrespharm.1720077.

ISNAD

Soylemez, Sumeyra Lubeyne - Dayan, Akın - Demirtunç, Refik - Sancar, Mesut. “The Effect of Clinical Pharmacist-Led Services With One-Year Follow-up in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial”. Journal of Research in Pharmacy 30/2 (March 1, 2026): 730-742. https://doi.org/10.12991/jrespharm.1720077.

JAMA

1.Soylemez SL, Dayan A, Demirtunç R, Sancar M. The effect of clinical pharmacist-led services with one-year follow-up in patients with type 2 diabetes mellitus: a randomized controlled trial. J. Res. Pharm. 2026;30:730–742.

MLA

Soylemez, Sumeyra Lubeyne, et al. “The Effect of Clinical Pharmacist-Led Services With One-Year Follow-up in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial”. Journal of Research in Pharmacy, vol. 30, no. 2, Mar. 2026, pp. 730-42, doi:10.12991/jrespharm.1720077.

Vancouver

1.Sumeyra Lubeyne Soylemez, Akın Dayan, Refik Demirtunç, Mesut Sancar. The effect of clinical pharmacist-led services with one-year follow-up in patients with type 2 diabetes mellitus: a randomized controlled trial. J. Res. Pharm. 2026 Mar. 1;30(2):730-42. doi:10.12991/jrespharm.1720077